Paper Details

  1. Home
  2. Paper Details

Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.

Author: BelousovaElena, BerkowitzNoah, BisslerJohn J, BuddeKlemens, Christopher KingswoodJ, FranzDavid N, FrostMichael D, RidolfiAntonia, SauterMatthias, ZonnenbergBernard A

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Everolimus treatment does not appear to be nephrotoxic in patients with renal angiomyolipoma or subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Paper Details　
Original Abstract of the Article :
BACKGROUND: A reduction in renal angiomyolipoma volume observed with everolimus (EVE) treatment in patients with tuberous sclerosis complex (TSC) has been postulated to translate to clinical benefit by reducing the risk of renal hemorrhage and chronic renal failure. METHODS: The long-term effects o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545468/

データ提供：米国国立医学図書館（NLM）

Everolimus for Tuberous Sclerosis Complex: A Journey Through the Desert of Renal Complications

Tuberous sclerosis complex (TSC), like a desert sandstorm, can lead to complications affecting various organs, including the kidneys. This study, like a camel navigating a treacherous desert landscape, investigates the effects of everolimus, a medication used to treat TSC, on renal function. The researchers, using data from two Phase 3 clinical trials, found that everolimus did not appear to be nephrotoxic and may preserve renal function in most patients with TSC. This study offers a potential oasis of hope for patients with TSC, suggesting that everolimus may help manage renal complications associated with the condition.

A Oasis of Renal Protection in the Desert of TSC

The study's findings reveal a potential oasis of renal protection in the desert of TSC. Everolimus, like a refreshing spring in the sands, appears to preserve renal function, offering a valuable benefit for patients with this condition. This discovery provides clinicians with a more effective and safe treatment option for managing renal complications associated with TSC.

Living Well in the Desert: Finding a Path to Kidney Health

This research, like a camel caravan carrying vital resources across a vast and unforgiving desert, reminds us of the importance of managing renal complications associated with TSC. By understanding the potential benefits of everolimus and other therapies, clinicians can provide a path to kidney health for patients with TSC, allowing them to navigate their health journey with greater strength and resilience.

Dr.Camel's Conclusion

This study, like a camel traversing a vast and unforgiving desert, offers a beacon of hope for those seeking to manage renal complications associated with tuberous sclerosis complex. The findings suggest that everolimus, like a well-placed oasis, may offer a safe and effective treatment option, potentially preserving renal function and improving overall well-being. It is a reminder that even in the face of seemingly insurmountable challenges, there is always the potential for progress and discovery.

Date :
  1. Date Completed 2020-04-14
  2. Date Revised 2020-04-14
Further Info :

Pubmed ID

30053159

DOI: Digital Object Identifier

PMC6545468

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.